|
Advisory for Securities Analysts, Investors and News Media
FRAZER, Pa., Dec. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc.
(Nasdaq: CEPH) will broadcast its investor and analyst meeting from Noon to
3 p.m. U.S. EST on Monday, December 19, 2005 via the Internet. The Cephalon
management team will discuss the companys product and research and
development initiatives.
The remarks will be webcast via the Investor Section of the Cephalon
website at http://www.cephalon.com and the remarks will be archived for one
week following the broadcast. A corresponding presentation will be available
on the website during the presentations.
Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and marketing of innovative
products to treat sleep and neurological disorders, cancer and pain.
Cephalon currently employs approximately 2,600 people in the United States
and Europe. U.S. sites include the companys headquarters in Frazer,
Pennsylvania, and offices, laboratories or manufacturing facilities in West
Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis,
Minnesota. Cephalons European headquarters are located in Maisons-Alfort,
France and other European offices are located in Guildford, England, and
Martinsried, Germany.
The company currently markets four proprietary products in the United
States: PROVIGIL(R) (modafinil) [C-IV], GABITRIL(R) (tiagabine hydrochloride),
ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] and TRISENOX(R) (arsenic
trioxide) injection and more than 20 products internationally. Full
prescribing information for all U.S. products is available at
http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Cephalons current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs, development of potential pharmaceutical
products, interpretation of clinical results, including the results of
clinical trials, prospects for final regulatory approval of compounds in
development, the anticipated timetable for the launch of products,
manufacturing development and capabilities, market prospects for its products,
sales and earnings guidance, and other statements regarding matters that are
not historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other words
and terms of similar meaning. Cephalons performance and financial results
could differ materially from those reflected in these forward-looking
statements due to general financial, economic, regulatory and political
conditions affecting the biotechnology and pharmaceutical industries as well
as more specific risks and uncertainties facing Cephalon such as those set
forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect. Therefore, you
should not rely on any such factors or forward-looking statements.
Furthermore, Cephalon does not intend to update publicly any forward-looking
statement, except as required by law. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
|
|
